A randomised, double- blind, 2 way cross-over study to determine 24-hour FEV1-time profile of inhaled tiotropium, delivered via the Respimat inhaler, after 4 weeks of once daily [5 Mcg in the evening (2 actuations of 2.5 Mcg)] or twice daily [2.5 Mcg in the morning and evening (2 actuations of 1.25 Mcg)] administration in patients with moderate persistent asthma.
Phase of Trial: Phase II
Latest Information Update: 01 Apr 2018
At a glance
- Drugs Tiotropium bromide (Primary)
- Indications Asthma
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 01 Apr 2018 Results of pooled data from vitro compared with nine clinical trial assessing PK exposure to tiotropium in preschool children with persistent asthmatic symptoms (using test VHC), were published in the Respiratory Medicine.
- 01 Jun 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.